Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Overview of attention for article published in Journal for Immunotherapy of Cancer, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 100 tweets from 77 users, with an upper bound of 197,051 followers.

遺伝子変異が、免疫療法への効果にも関わる、、、犬でも、去勢に反応しないのもいるもんなー。いやぁ。深い。 https://t.co/StYeytz7Vv

@SKCCDirector Great pt to bring knowledge from multiple cancers to better understand the impact of individual DDR aberrations! Shouldn't give up yet on PARP in #bladdercancer noting some success in #prostatecancer for combo w #immunohterapy. #Worktodo! @AS

RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 96 additional tweets.